Success Metrics

Clinical Success Rate
87.8%

Based on 108 completed trials

Completion Rate
88%(108/123)
Active Trials
4(2%)
Results Posted
21%(23 trials)
Terminated
15(9%)

Phase Distribution

Ph phase_4
1
1%
Ph phase_1
34
21%
Ph phase_3
2
1%
Ph not_applicable
15
9%
Ph phase_2
24
15%

Phase Distribution

34

Early Stage

24

Mid Stage

3

Late Stage

Phase Distribution76 total trials
Phase 1Safety & dosage
34(44.7%)
Phase 2Efficacy & side effects
24(31.6%)
Phase 3Large-scale testing
2(2.6%)
Phase 4Post-market surveillance
1(1.3%)
N/ANon-phased studies
15(19.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

108 of 135 finished

Non-Completion Rate

20.0%

27 ended early

Currently Active

4

trials recruiting

Total Trials

164

all time

Status Distribution
Active(4)
Completed(108)
Terminated(27)
Other(25)

Detailed Status

Completed108
unknown25
Terminated15
Withdrawn12
Active, not recruiting3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
164
Active
4
Success Rate
87.8%
Most Advanced
Phase 4

Trials by Phase

Phase 134 (44.7%)
Phase 224 (31.6%)
Phase 32 (2.6%)
Phase 41 (1.3%)
N/A15 (19.7%)

Trials by Status

withdrawn127%
unknown2515%
recruiting11%
completed10866%
active_not_recruiting32%
terminated159%

Recent Activity

Clinical Trials (164)

Showing 20 of 164 trialsScroll for more
NCT01199562

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Active Not Recruiting
NCT00335816Phase 2

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Active Not Recruiting
NCT00898235

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

Recruiting
NCT00977457Phase 1

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

Active Not Recruiting
NCT00873275Phase 1

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Completed
NCT00483366Phase 1

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Completed
NCT00720304Phase 2

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Completed
NCT00667563Phase 1

Vaccine Therapy in Preventing HPV in HIV-Positive Women in India

Completed
NCT01206465Phase 1

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

Completed
NCT00611351Phase 2

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Completed
NCT01004640

Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Unknown
NCT00900224

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Unknown
NCT04445532

Hepatobiliary Tumors Tissue Samples Acquisition

Unknown
NCT00499291Not Applicable

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Withdrawn
NCT01165645Not Applicable

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Withdrawn
NCT00945269Phase 1

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Terminated
NCT01005368

Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Completed
NCT00900055

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Completed
NCT03209063

The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage

Unknown
NCT05384886

Impact of New Variants and Vaccines on the Course of COVID-19

Completed

Drug Details

Intervention Type
GENETIC
Total Trials
164